Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC): ASCO 41th Annual Meeting Proceedings. - Escudier,B.; Szczylik,C.; Eisen,T. (Orlando, FL, ASCO, 2005)